Skip to main content
NCBI home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2002;21(1):57–83. doi: 10.1385/MB:21:1:057

Validation of biopharmaceutical purification processes for virus clearance evaluation

Allan Darling 1,✉
PMCID: PMC7090984  PMID: 11989660

Abstract

Any biopharmaceutical product that has involved the use of animal-derived material during the manufacturing process has the potential to be contaminated with animal viruses. To ensure safety of these products, extensive testing is performed on the starting materials, such as the cell banks, and on the raw materials used in manufacture. Additional testing is also performed at various stages of production and, in some cases, on the final product as well. Because of inherent limitations in direct testing methods, the capacity of the downstream purification process to remove/inactivate potential viral contaminants is also studied to give an extra degree of assurance that the final product will be free of infectious viruses.

Index Entries: Viral clearance, biosafety testing, biopharmaceutical, viral safety, viral validation

References

  • 1.Biologicals Control Act of 1902 (1902).
  • 2.Fox J. P., Lennette E. H., Manso C., Aquiar J. R. Observation on the occurrence of icterus in Brazil following vaccination against yellow fever. Am. J. Hyg. 1942;36:68–116. [Google Scholar]
  • 3.Harris R. J. C., Dougherty R. M., Biggs P. M., Payne L. N., Goffe A. P., Churchill A. E. Contaminant viruses in two live virus vaccines produced in chick cells. J. Hyg. (Cambridge) 1966;64:1–6. doi: 10.1017/s0022172400040286. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Murray R. First International Conference on Vaccines against Viral and Rickettsial Diseases of Man. Washington D.C.: Pan American Health Organization, WHO; 1967. Contemporary problems in regulating the potency and safety of viral vaccines; pp. 577–580. [Google Scholar]
  • 5.Brown P., Gajdusek D. C., Gibbs C. J., Asher D. H. Potential epidemic of Creutzfeld-Jacob disease from human growth hormone therapy. N. Engl. J. Med. 1985;313:728–731. doi: 10.1056/NEJM198509193131205. [DOI] [PubMed] [Google Scholar]
  • 6.Ben-Hur E., Horowitz B. Virus Inactivation in blood. AIDS. 1996;10:1183–1190. doi: 10.1097/00002030-199609000-00027. [DOI] [PubMed] [Google Scholar]
  • 7.RL Garnick R. L. Viral Safety and Evaluation of Viral Clearance from Biopharmaceutical Products. Basel Karger: Dev. Biol. Stand.; 1996. Experience with viral contamination in cell culture; pp. 49–56. [PubMed] [Google Scholar]
  • 8.Willkommen, H. (1996) Presentation at BioEast Meeting, January, Washington DC.
  • 9.Kappeler A., Lutz-Wallace C., Sapp T., Sidhu M. Detection of bovine polyomavirus contamination in fetal bovine sera and modified live viral vaccines using polymerase chain reaction. Biologicals. 1996;24(2):131–135. doi: 10.1006/biol.1996.0017. [DOI] [PubMed] [Google Scholar]
  • 10.Harasawa R., Tomiyama T. Evidence of pestivirus RNA in human virus vaccines. J. Clin. Microbiol. 1994;32(6):1604–1604. doi: 10.1128/jcm.32.6.1604-1605.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Harasawa R., Mizusawa H. Demonstration and genotyping of pestivirus RNA from mammalian cell lines. Microbiol. Immunol. 1995;39(12):979–985. doi: 10.1111/j.1348-0421.1995.tb03301.x. [DOI] [PubMed] [Google Scholar]
  • 12.O’Toole D., Van Campen H., Woodard L. Bluetongue virus: contamination of vaccine. J. Am. Vet. Med. Assoc. 1994;1(3):407–407. [PubMed] [Google Scholar]
  • 13.Levings R. I., Wilbur L. A., Evermann J. F., et al. Abortion and death in pregnant bitches associated with a canine vaccine contaminated with blue-tongue virus. Viral Safety and Evaluation of Viral Clearance from Biopharmaceutical Products. 1996;88:219–220. [PubMed] [Google Scholar]
  • 14.Rabenau H., Ohlinger V., Anderson J., et al. Contamination of genetically engineered CHO-cells by epizootic haemorrhagic disease virus (EHDV) Biologicals. 1993;21(3):207–214. doi: 10.1006/biol.1993.1077. [DOI] [PubMed] [Google Scholar]
  • 15.Senda M., Parrish C. R., Harasawa R., et al. Detection by PCR of wild-type canine parvovirus which contaminates dog vaccines. J. Clin. Microbiol. 1995;33(1):110–113. doi: 10.1128/jcm.33.1.110-113.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Linnen J., Wages J., Zhang-Keck Z. Y., et al. Molecular cloning and disease association of hepatitis G virus: a transfusion-transmissible agent. Science. 1996;27:505–508. doi: 10.1126/science.271.5248.505. [DOI] [PubMed] [Google Scholar]
  • 17.Moore S. J., Gao G., Dominguez E., et al. Primary characterization of a herpesvirus agent associated with Kaposi’s sarcoma. J. Virol. 1996;70:549–558. doi: 10.1128/jvi.70.1.549-558.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.CPMP Ad Hoc Working Party on Biotechnology/Pharmacy. (1991) Note for Guidance: Validation of Virus Removal and Inactivation Procedures III/8115/89.
  • 19.Office of Biologics Research and Review, Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use (Food and Drug Administration, Bethesda, MD, 1987). [DOI] [PubMed]
  • 20.Federal Health Office and Paul Ehrlich Institute Federal Office for Sera and Vaccines Notice on the Registration of Drugs: Requirements for Validation Studies to Demonstrate the Virus Safety of Drugs Derived from Human Blood or Plasma. Bundesanzeiger. 1994;84:4742–4744. [Google Scholar]
  • 21.Federal Health Office and Paul Ehrlich Institute Federal Office for Sera and Vaccines Announcement on Measures for Averting Risks from Medicinal Products. (1994) Reducing the Risk of Transmitting Haematogenous Viruses with Medicinal Products made by Fractionation from Plasma of Human Origin.
  • 22.The European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit-CPMP Biotechnology Working Party Note for Guidance on Virus Validation Studies: the Design, Contribution and Interpretation of Studies Validating the Inactivation and Removal of Viruses, (CPMP/BWP/268/95 Final Version 2, Canary Wharf, London, 1996).
  • 23.The European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit — CPMP Biotechnology Working Party Medicinal Products Derived from Human Plasma, (CPMP/BWP/268/95 Final Version 2, Canary Wharf, London, 1996).
  • 24.Office of Biologics Research and Review, Points to Consider in the Characterization of Cell Lines Used to Produce Biologicals (Food and Drug Administration, Bethesda, MD, 1993).
  • 25.Office of Biologics Research and Review, Draft Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use (Food and Drug Administration, Bethesda, MD, 1994).
  • 26.Center for Biologics Evaluation and Research, Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use (Food and Drug Administration, Rockville, MD, 1997). [DOI] [PubMed]
  • 27.ICH Topic Q5A. Step 4 Consensus Guideline, Quality of Biotechnological Products: Viral Safety Evaluation of Biotechnology Products Derived From Cell Lines of Human or Animal Origin, CPMP/ICH/295/95. The European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit, Canary Wharf, London (1997).
  • 28.Sofer G. Validation: Ensuring the accuracy of scaled-down chromatography models. Biopharm. 1996;9(9):51–54. [Google Scholar]
  • 29.Darling A. J., Kreuzberg-Duffy U., Borland L., Morrow A., Berglof J. H., Andersson I. Validation of chromatographic procedures used in the fractionation of plasma derivatives. In: Spier R. E., Griffith J. B., Berthold W., editors. Animal Cell Technology: Products of Today, Prospects for Tomorrow. Oxford: Butterworth-Heinemann Ltd.; 1994. pp. 567–570. [Google Scholar]
  • 30.Hyclone Laboratories Inc. Freezing and Thawing Serum and Other Biological Materials. Art to Science. 1992;11(2):1–7. [Google Scholar]
  • 31.ICH Guideline on “Validation of Analytical Procedures: Definitions and Terminology; Availability,” Federal Register 4, 11,259–11,262, (1 March 1995).
  • 32.Darling A. J., Spaltro J. J. Process Validation for Virus Removal. Considerations for Design of Process Studies and Viral Assays. BioPharm. 1996;9(9):42–50. [Google Scholar]
  • 33.Spearman C., Kaerber G. In: Virologische Arbeitsmethoden. Bibrack B., Wittmann G., editors. Stuttgart: Fischer Verlag; 1974. pp. 37–39. [Google Scholar]
  • 34.Little, L. E. (1995) Validation of Immunological and Biological Assays. BiopharmNov. 36–42.
  • 35.United States vs Barr Laboratories, Inc.; Civil Action No. 92–1744, U.S. District Court for the District of New Jersey; 812F. Supp. 458; 1993 U.S. Dist. Lexis 1932; 4 February 1993, as amended 30 March 1993.
  • 36.Prusiner S. B. The prion diseases. Sci. Am. 1995;272(1):48–51. doi: 10.1038/scientificamerican0195-48. [DOI] [PubMed] [Google Scholar]
  • 37.Westaway D., Carlson G. A., Prusiner S. B. On safari with PrP: prion diseases of animals. Trends Microbiol. 1995;3(4):141–147. doi: 10.1016/S0966-842X(00)88903-9. [DOI] [PubMed] [Google Scholar]
  • 38.Note for Guidance on Minimizing the Risk of Transmitting Animal Spongiform Encephalopathy Agents via Human and Veterinary Medicinal Products — CPMP/CVMP EMEA/410/01 — February 2001.
  • 39.Notification of the Safety Requirements for Pharmaceuticals Made From Body Components of Cattle, Sheep or Goats for the Protection Against the Risk of Transmission of BSE and Scrapie — BGA, Germany Feb. 1994.
  • 40.Notification Concerning the Approval and Registration of Pharmaceuticals of 28 March 1996 Protection Against Pharmaceutical Product Risks, Level II — BfArM, Federal Institute for Pharmaceuticals and Medicinal Products, Germany.
  • 41.Will R. G., Ironside J. W., Zeilder M., et al. A New Variant of Creutzfeldt-Jakob Disease in the UK. Lancet. 1996;374:921–925. doi: 10.1016/S0140-6736(96)91412-9. [DOI] [PubMed] [Google Scholar]
  • 42.Lasmezas C. I., Deslys J.-P., Demaimay R., et al. BSE Transmission to Macaques. Nature. 1996;381:743–743. doi: 10.1038/381743a0. [DOI] [PubMed] [Google Scholar]
  • 43.Telling C., Scott M., Hsiao K. K., et al. Transmission of Creutzfeldt-Jakob disease from humans to transgenic mice expressing chimeric human-mouse prion protein. Proc. Natl. Acad. Sci. USA. 1994;91:9936–9940. doi: 10.1073/pnas.91.21.9936. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Houston F., Foster J. D., Chong A., Hunter N., Bostock C. J. Transmission of BSE by blood transfusion in sheep. Lancet. 2000;356:999–1000. doi: 10.1016/S0140-6736(00)02719-7. [DOI] [PubMed] [Google Scholar]
  • 45.Lee D. C., Stenland C. J., Hartwell R. C., et al. Monitoring plasma processing steps with a sensitive Western Blot assay for the detection of prion protein. J. Virol. Methods. 2000;84:77–89. doi: 10.1016/S0166-0934(99)00135-4. [DOI] [PubMed] [Google Scholar]

Articles from Molecular Biotechnology are provided here courtesy of Nature Publishing Group

RESOURCES